Describe Carcinoma of the Anal Canal in detail.

The Concept

Carcinoma of the anal canal is important partly because it differs from the cancers just above it: whereas rectal and colonic cancers are adenocarcinomas, anal canal cancer is usually a squamous cell carcinoma (reflecting the squamous lining of the lower canal). It is strongly associated with human papillomavirus (HPV, types 16/18), anoreceptive intercourse, HIV and immunosuppression, and chronic irritation.

Clinical Features & Spread

It presents with anal bleeding, pain, a mass or ulcer, pruritus, tenesmus, a change in bowel habit, and eventually incontinence. Its lymphatic spread depends on the level: lesions below the dentate line drain to the inguinal lymph nodes, while those above drain to the pelvic/mesorectal nodes — so the groins must be examined.

Investigation & Management

Diagnosis is by examination and biopsy, with MRI and assessment of the lymph nodes for staging. The key management point is that, unlike rectal cancer, the first-line treatment is chemoradiotherapy (the Nigro regimen — 5-fluorouracil and mitomycin with radiotherapy), which is sphincter-preserving and often curative. Radical surgery (abdominoperineal resection) is reserved for residual or recurrent disease.

A Note on the Contrast with Rectal Cancer

The contrast with rectal cancer is instructive and examinable. Rectal adenocarcinoma is treated primarily by surgery (with neoadjuvant chemoradiotherapy for advanced disease), whereas anal squamous cell carcinoma is treated primarily by chemoradiotherapy (Nigro regimen), with surgery held in reserve. This difference — driven by the different histology (adenocarcinoma vs squamous) and the desire to preserve the sphincter — is a key point, as is the different lymphatic drainage (inguinal nodes for lower anal lesions).

The Bottom Line

Anal canal carcinoma is usually an HPV-related squamous cell carcinoma treated first-line by sphincter-preserving chemoradiotherapy (Nigro regimen), with surgery reserved for residual or recurrent disease — contrasting with the surgical treatment of rectal adenocarcinoma.

A Note on Screening & Prevention

Because anal cancer is strongly linked to HPV, there is an important preventive dimension: HPV vaccination reduces the risk of the disease, and surveillance (anal cytology/examination) of high-risk groups — particularly HIV-positive individuals and other immunosuppressed patients — allows detection of premalignant anal intraepithelial neoplasia (AIN) before invasive cancer develops. This parallels cervical screening and reflects the shared HPV aetiology, making prevention and early detection a genuine part of managing anal cancer risk.

A Note on the Inguinal Nodes

A practical examination point is the importance of the inguinal lymph nodes in anal cancer. Because lesions below the dentate line drain to the groin, palpable inguinal lymphadenopathy may represent nodal metastasis and must be assessed (by examination, imaging and, if needed, biopsy) as it affects staging and the radiotherapy field. This differs from rectal cancer, which spreads to mesorectal and pelvic nodes, and it is why the groins are always examined in a patient with a suspected anal canal tumour.

Chemoradiation (Nigro regimen) is preferred over primary surgery.

• Anal canal carcinoma = usually squamous cell carcinoma (vs adenocarcinoma of rectum/colon); linked to HPV (16/18), anoreceptive intercourse, HIV/immunosuppression.
• Bleeding, pain, mass/ulcer, pruritus, tenesmus, incontinence; below dentate line → inguinal nodes, above → pelvic nodes.
• Diagnose by biopsy + MRI/node assessment.
• First-line = chemoradiotherapy (Nigro regimen: 5-FU + mitomycin + radiotherapy), sphincter-preserving; surgery (APR) for residual/recurrent disease.